Levobupivacaine Kabi (Levobupivacaine Hydrochloride)

• Levobupivacaine is a long‑acting amide local anesthetic used in the management of pain associated with surgical and obstetric procedures.
• Surgical anesthesia: provides dense sensory block for operative procedures.
• Postoperative analgesia: extends pain relief after surgery, reducing opioid requirement.
• Labor analgesia: offers effective neuraxial analgesia during childbirth.

• Levobupivacaine blocks voltage‑gated sodium channels on neuronal membranes, inhibiting the initiation and propagation of nerve impulses. By preferentially affecting sensory fibers and exhibiting high protein binding, it produces prolonged loss of sensation with limited motor block, resulting in effective anesthesia and analgesia for the duration of the procedure.

Adverse reactions may occur following administration of levobupivacaine.

Common Side Effects

• Hypotension: transient drop in blood pressure.
• Bradycardia: slowed heart rate.
• Dizziness or light‑headedness.
• Nausea or vomiting.
• Metallic taste or oral paraesthesia.
• Injection site pain or irritation.

Serious or Rare Side Effects

• Cardiac arrhythmias or conduction disturbances.
• Seizures, especially with high plasma concentrations.
• Respiratory depression or apnea.
• Allergic reactions including rash, urticaria, or anaphylaxis.
• Methemoglobinemia.
• Central nervous system toxicity presenting as tinnitus or visual disturbances.

Careful patient assessment and monitoring are essential when using levobupivacaine.

• Hepatic impairment: reduce dose and monitor plasma levels.
• Known hypersensitivity: avoid use in patients with documented allergy to amide local anesthetics.
• Cardiovascular status: monitor heart rate and blood pressure during administration.
• Obstetric patients: use the lowest effective dose for labor analgesia.
• Concomitant CNS depressants: observe for enhanced sedation.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Levobupivacaine may interact with other drugs, influencing safety and efficacy.

Major Interactions (Avoid)

• Other local anesthetics: risk of cumulative toxicity.
• Potent CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase plasma concentrations.
• Drugs lowering seizure threshold (e.g., bupropion, tramadol): heighten risk of seizures.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may exacerbate bradycardia.
• Vasodilators: can enhance hypotensive effects.
• Anticoagulants/antiplatelet agents: increase bleeding risk with neuraxial techniques.
• Diuretics: may affect plasma protein binding.
• General anesthetics: monitor for additive CNS depression.